Patents by Inventor Toshio Yoshizawa
Toshio Yoshizawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220363684Abstract: Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.Type: ApplicationFiled: January 7, 2022Publication date: November 17, 2022Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Shingo YAMAMOTO, Toshio YOSHIZAWA
-
Publication number: 20220177474Abstract: The purinone derivative 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one hydrochloride has Btk-selective inhibitory activity and, in addition to having excellent metabolic stability, it is a compound that exhibits a high level of solubility and absorption with respect to the free base and can be crystallized, hence it can serve as a therapeutic agent for diseases involving B cells and mast cells.Type: ApplicationFiled: February 24, 2022Publication date: June 9, 2022Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Shingo YAMAMOTO, Toshio YOSHIZAWA
-
Patent number: 11292795Abstract: The purinone derivative 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one hydrochloride has Btk-selective inhibitory activity and, in addition to having excellent metabolic stability, it is a compound that exhibits a high level of solubility and absorption with respect to the free base and can be crystallized, hence it can serve as a therapeutic agent for diseases involving B cells and mast cells.Type: GrantFiled: September 16, 2020Date of Patent: April 5, 2022Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Shingo Yamamoto, Toshio Yoshizawa
-
Publication number: 20210009593Abstract: The purinone derivative 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one hydrochloride has Btk-selective inhibitory activity and, in addition to having excellent metabolic stability, it is a compound that exhibits a high level of solubility and absorption with respect to the free base and can be crystallized, hence it can serve as a therapeutic agent for diseases involving B cells and mast cells.Type: ApplicationFiled: September 16, 2020Publication date: January 14, 2021Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Shingo YAMAMOTO, Toshio YOSHIZAWA
-
Patent number: 10807981Abstract: The purinone derivative 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one hydrochloride has Btk-selective inhibitory activity and, in addition to having excellent metabolic stability, it is a compound that exhibits a high level of solubility and absorption with respect to the free base and can be crystallized, hence it can serve as a therapeutic agent for diseases involving B cells and mast cells.Type: GrantFiled: June 25, 2019Date of Patent: October 20, 2020Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Shingo Yamamoto, Toshio Yoshizawa
-
Publication number: 20200171153Abstract: The present invention is directed to the combination therapy of an anti-CD20 antibody with a BTK inhibitor for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with a type I anti-CD20 antibody or an afucosylated humanized B-Ly1 antibody and a BTK inhibitor.Type: ApplicationFiled: November 11, 2019Publication date: June 4, 2020Inventors: Christian Klein, Toshio Yoshizawa, Tomoko Yasuhiro
-
Publication number: 20200048256Abstract: Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.Type: ApplicationFiled: October 16, 2019Publication date: February 13, 2020Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Shingo YAMAMOTO, Toshio YOSHIZAWA
-
Patent number: 10487085Abstract: Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.Type: GrantFiled: February 7, 2019Date of Patent: November 26, 2019Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Shingo Yamamoto, Toshio Yoshizawa
-
Publication number: 20190315748Abstract: The purinone derivative 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one hydrochloride has Btk-selective inhibitory activity and, in addition to having excellent metabolic stability, it is a compound that exhibits a high level of solubility and absorption with respect to the free base and can be crystallized, hence it can serve as a therapeutic agent for diseases involving B cells and mast cells.Type: ApplicationFiled: June 25, 2019Publication date: October 17, 2019Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Shingo YAMAMOTO, Toshio YOSHIZAWA
-
Patent number: 10426778Abstract: To provide a medicament which shows more remarkable effect in treatment of activated B-cell like diffuse large B-cell lymphoma ABC-DLBCL than the existing Btk inhibitor, and is excellent in safety. The present compound exhibits more remarkable effect in treatment of activated B-cell like diffuse large B-cell lymphoma (ABC-DLBCL) patients, inter alia, ABC-DLBCL patients having CD79B wild-type gene background than the existing Btk inhibitor, and therefore, it can attain the object of the present invention.Type: GrantFiled: October 23, 2018Date of Patent: October 1, 2019Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Toshio Yoshizawa, Ryohei Kozaki
-
Patent number: 10370377Abstract: The purinone derivative 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one hydrochloride has Btk-selective inhibitory activity and, in addition to having excellent metabolic stability, it is a compound that exhibits a high level of solubility and absorption with respect to the free base and can be crystallized, hence it can serve as a therapeutic agent for diseases involving B cells and mast cells.Type: GrantFiled: April 27, 2018Date of Patent: August 6, 2019Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Shingo Yamamoto, Toshio Yoshizawa
-
Publication number: 20190169192Abstract: Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.Type: ApplicationFiled: February 7, 2019Publication date: June 6, 2019Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Shingo YAMAMOTO, Toshio YOSHIZAWA
-
Patent number: 10233185Abstract: Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.Type: GrantFiled: February 13, 2018Date of Patent: March 19, 2019Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Shingo Yamamoto, Toshio Yoshizawa
-
Publication number: 20190054091Abstract: To provide a medicament which shows more remarkable effect in treatment of activated B-cell like diffuse large B-cell lymphoma (ABC-CLBCL) than the existing Btk inhibitor, and is excellent in safety. The present compound exhibits more remarkable effect in treatment of activated B-cell like diffuse large B-cell lymphoma (ABC-DLBCL) patients, inter alia, ABC-DLBCL patients having CD79B wild-type gene background than the existing Btk inhibitor, and therefore, it can attain the object of the present invention.Type: ApplicationFiled: October 23, 2018Publication date: February 21, 2019Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Toshio YOSHIZAWA, Ryohei KOZAKI
-
Publication number: 20190054090Abstract: Provided herein are methods relating to a therapeutic strategy for treatment of cancer, including hematological malignancies. In particular, the methods include administration of a Btk inhibitor and a checkpoint inhibitor, including combinations in which the Btk inhibitor is 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one, or a pharmaceutically acceptable salt thereof, and the checkpoint inhibitor is selected from inhibitors of PD-1, PD-L1, and CTLA-4.Type: ApplicationFiled: September 30, 2016Publication date: February 21, 2019Inventors: Sriram Venkataraman, Daniel B. Tumas, Kohei Tanaka, Tomoko Yasuhiro, Toshio Yoshizawa
-
Publication number: 20180353512Abstract: Provided herein are methods that relate to a therapeutic strategy for treatment of a B-cell malignancy. In particular, the methods include administration of a PI3K inhibitor and a BTK inhibitor.Type: ApplicationFiled: June 22, 2016Publication date: December 13, 2018Inventors: Helen Collins, Julie Di Paolo, Kathy Keegan, Ryohei Kozaki, Sarah Meadows, Cara Nelson, Christophe Queva, Srinivasan Ramanathan, Stacey Tannheimer, Daniel Tumas, Tomoko Yasuhiro, Toshio Yoshizawa
-
Patent number: 10137129Abstract: To provide a medicament which shows more remarkable effect in treatment of activated B-cell like diffuse large B-cell lymphoma (ABC-CLBCL) than the existing Btk inhibitor, and is excellent in safety. The present compound exhibits more remarkable effect in treatment of activated B-cell like diffuse large B-cell lymphoma (ABC-DLBCL) patients, inter alia, ABC-DLBCL patients having CD79B wild-type gene background than the existing Btk inhibitor, and therefore, it can attain the object of the present invention.Type: GrantFiled: July 13, 2016Date of Patent: November 27, 2018Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Toshio Yoshizawa, Ryohei Kozaki
-
Publication number: 20180244675Abstract: The purinone derivative 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one hydrochloride has Btk-selective inhibitory activity and, in addition to having excellent metabolic stability, it is a compound that exhibits a high level of solubility and absorption with respect to the free base and can be crystallized, hence it can serve as a therapeutic agent for diseases involving B cells and mast cells.Type: ApplicationFiled: April 27, 2018Publication date: August 30, 2018Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Shingo YAMAMOTO, Toshio YOSHIZAWA
-
Publication number: 20180170933Abstract: Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.Type: ApplicationFiled: February 13, 2018Publication date: June 21, 2018Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Shingo YAMAMOTO, Toshio YOSHIZAWA
-
Patent number: 9981966Abstract: The purinone derivative 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one hydrochloride has Btk-selective inhibitory activity and, in addition to having excellent metabolic stability, it is a compound that exhibits a high level of solubility and absorption with respect to the free base and can be crystallized, hence it can serve as a therapeutic agent for diseases involving B cells and mast cells.Type: GrantFiled: July 19, 2017Date of Patent: May 29, 2018Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Shingo Yamamoto, Toshio Yoshizawa
